{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:19:09Z","timestamp":1793038749631,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.autrev.2009.11.004","type":"journal-article","created":{"date-parts":[[2009,11,12]],"date-time":"2009-11-12T00:43:10Z","timestamp":1257986590000},"page":"A305-A310","source":"Crossref","is-referenced-by-count":293,"title":["The geoepidemiology of Sj\u00f6gren's syndrome"],"prefix":"10.1016","volume":"9","author":[{"given":"Clio P.","family":"Mavragani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haralampos M.","family":"Moutsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.autrev.2009.11.004_bib1","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/archinte.164.12.1275","article-title":"Clinical manifestations and early diagnosis of Sjogren syndrome","volume":"164","author":"Kassan","year":"2004","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.autrev.2009.11.004_bib2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/03009740600759860","article-title":"Comparison of the different classification criteria sets for primary Sj\u00f6gren's syndrome","volume":"35","author":"Novljan","year":"2006","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2009.11.004_bib3","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2009.11.004_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000024423","article-title":"Sj\u00f6gren's syndrome: autoantibodies to cellular antigens. Clinical and molecular aspects","volume":"123","author":"Mavragani","year":"2000","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2009.11.004_bib5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/ar2669","article-title":"Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases","volume":"11","author":"Gabriel","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.autrev.2009.11.004_bib6","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/ard.2007.073650","article-title":"Prevalence of Sjogren syndrome among Nagasaki atomic bomb survivors","volume":"67","author":"Hida","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2009.11.004_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/03009740701678712","article-title":"Estimation of the prevalence of primary Sj\u00f6gren's syndrome in two age-different community-based populations using two sets of classification criteria: the Hordaland Health Study","volume":"37","author":"Haugen","year":"2008","journal-title":"Scand J Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2009.11.004_bib8","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.3899\/jrheum.081326","article-title":"Increased prevalence of antibodies to thyroid peroxidase in dry eyes and mouth syndrome or sicca asthenia polyalgia syndrome","volume":"36","author":"Mavragani","year":"2009","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2009.11.004_bib9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s12016-007-8011-8","article-title":"T lymphocytes in Sj\u00f6gren's syndrome: contributors to and regulators of pathophysiology","volume":"32","author":"Katsifis","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2009.11.004_bib10","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1002\/art.23073","article-title":"Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjogren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development","volume":"56","author":"Manoussakis","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2009.11.004_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s12016-007-8004-7","article-title":"Persistent viral infection in primary Sjogren's syndrome: review and perspectives","volume":"32","author":"Triantafyllopoulou","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2009.11.004_bib12","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/art.20998","article-title":"Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism","volume":"52","author":"Bave","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2009.11.004_bib13","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1186\/ar1912","article-title":"B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome","volume":"8","author":"Ittah","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.autrev.2009.11.004_bib14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-3083.2005.01688.x","article-title":"The BAFF\/APRIL system in systemic autoimmune diseases with a special emphasis on Sjogren's syndrome","volume":"62","author":"Szodoray","year":"2005","journal-title":"Scand J Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2009.11.004_bib15","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-2249.2002.01869.x","article-title":"The Th1\/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome","volume":"128","author":"Mitsias","year":"2002","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2009.11.004_bib16","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2353\/ajpath.2009.090319","article-title":"Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome immunopathogenesis","volume":"175","author":"Katsifis","year":"2009","journal-title":"Am J Pathol"},{"issue":"8","key":"10.1016\/j.autrev.2009.11.004_bib17","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1084\/jem.20090585","article-title":"Loss of the lupus autoantigen Ro52\/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway","volume":"206","author":"Espinosa","year":"2009","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.autrev.2009.11.004_bib18","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.4049\/jimmunol.181.4.2898","article-title":"Identification of IL-18 and Th17 cells in salivary glands of patients with Sjogren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18","volume":"181","author":"Sakai","year":"2008","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2009.11.004_bib19","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/art.23214","article-title":"Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren's syndrome: findings in humans and mice","volume":"58","author":"Nguyen","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2009.11.004_bib20","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.2353\/ajpath.2009.081058","article-title":"Sjogren's syndrome-like ocular surface disease in thrombospondin-1 deficient mice","volume":"175","author":"Turpie","year":"2009","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.autrev.2009.11.004_bib21","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2353\/ajpath.2008.080246","article-title":"Foxp3+ T-regulatory cells in Sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors","volume":"173","author":"Christodoulou","year":"2008","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.autrev.2009.11.004_bib22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12016-007-8007-4","article-title":"The role of epithelial cells in the pathogenesis of Sjogren's syndrome","volume":"32","author":"Manoussakis","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"issue":"Suppl 11","key":"10.1016\/j.autrev.2009.11.004_bib23","first-page":"S9","article-title":"Autoimmune epitheliitis: Sjogren's syndrome","volume":"12","author":"Skopouli","year":"1994","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2009.11.004_bib24","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/BOR.0b013e32832f0861","article-title":"Genetics of systemic lupus erythematosus and Sjogren's syndrome","volume":"21","author":"Scofield","year":"2009","journal-title":"Curr Opin Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2009.11.004_bib25","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1002\/art.23142","article-title":"Association of an IRF5 gene functional polymorphism with Sjogren's syndrome","volume":"56","author":"Miceli-Richard","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.autrev.2009.11.004_bib26","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/art.24662","article-title":"The CGGGG insertion\/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjogren's syndrome","volume":"60","author":"Miceli-Richard","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2009.11.004_bib27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/gene.2008.1","article-title":"Variant form of STAT4 is associated with primary Sjogren's syndrome","volume":"9","author":"Korman","year":"2008","journal-title":"Genes Immun"},{"issue":"1","key":"10.1016\/j.autrev.2009.11.004_bib28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/gene.2008.94","article-title":"Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjogren's syndrome","volume":"10","author":"Nordmark","year":"2009","journal-title":"Genes Immun"},{"key":"10.1016\/j.autrev.2009.11.004_bib29","article-title":"Association of copy number variation in the FCGR3B gene with risk of autoimmune diseases","author":"Mamtani","year":"2009","journal-title":"Genes Immun"},{"key":"10.1016\/j.autrev.2009.11.004_bib30","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1586\/1744666X.3.4.579","article-title":"Activation of Type I interferon in systemic lupus erythematosus","volume":"3","author":"Kirou","year":"2007","journal-title":"Exp Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2009.11.004_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/ard.2007.084152","article-title":"Stress, coping strategies and social support in patients with primary Sjogren's syndrome prior to disease onset: a retrospective case-control study","volume":"68","author":"Karaiskos","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"34","key":"10.1016\/j.autrev.2009.11.004_bib32","doi-asserted-by":"crossref","first-page":"12628","DOI":"10.1073\/pnas.0405099101","article-title":"Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren's syndrome","volume":"101","author":"Shim","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.autrev.2009.11.004_bib33","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1002\/art.22828","article-title":"Low salivary dehydroepiandrosterone and androgen-regulated cysteine-rich secretory protein 3 levels in Sjogren's syndrome","volume":"56","author":"Laine","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2009.11.004_bib34","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/ncprheum0165","article-title":"The management of Sjogren's syndrome","volume":"2","author":"Mavragani","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2009.11.004_bib35","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1002\/art.23062","article-title":"Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept","volume":"56","author":"Mavragani","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2009.11.004_bib36","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/rheumatology\/kep228","article-title":"Usefulness of initial histological features for stratifying Sjogren's syndrome responders to mizoribine therapy","volume":"48","author":"Nakayamada","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.autrev.2009.11.004_bib37","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/ncprheum0823","article-title":"Is mizoribine a new therapeutic agent for Sjogren's syndrome?","volume":"4","author":"Moutsopoulos","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2009.11.004_bib38","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/rheumatology\/kep104","article-title":"Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome","volume":"48","author":"Rihl","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.autrev.2009.11.004_bib39","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1007\/s00415-009-5175-6","article-title":"Efficacy of tacrolimus in Sjogren's syndrome-associated CNS disease with aquaporin-4 autoantibodies","volume":"256","author":"Fukuda","year":"2009","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2009.11.004_bib40","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2008.092601","article-title":"Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment","volume":"68","author":"Meijer","year":"2009","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997209001827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997209001827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T15:57:25Z","timestamp":1558627045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997209001827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S1568997209001827"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2009.11.004","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}